2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2747 Low observed hepatitis B virus reactivation and comparable clinical outcomes by HBV serostatus after CD7 CAR T-cell therapy: A multicenter study

Ruoxuan Zhang Jr, Yang Cao, MD2, Xiaoxia Hu, MD3, Yang Xu, MD4, Su Li5
1 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
5 Department of Hematology, Liquan Hospital, GoBroad Medical Institute of Hematology (Shanghai Center), Shanghai, China
Background

Hepatitis B virus reactivation (HBVr) is a recognized complication of B-cell–directed CAR T-cell therapy, whereas its risk after CD7-directed therapy remains poorly defined. CD7 CAR T-cell therapy is followed by expansion of non-CAR CD7-negative T cells and recovery of CD7-negative natural killer cells, raising the hypothesis that its distinct immune-reconstitution pattern may preserve antiviral immune surveillance.

Methods

We conducted a multicenter retrospective cohort study of 93 patients with T-cell malignancies treated with CD7 CAR T cells. Clinical outcomes were compared between patients with no prior HBV infection (No; n=43) and resolved HBV infection (Resolved; HBsAg-negative/anti-HBc-positive; n=47); 3 HBsAg-positive patients were analyzed descriptively. Toxicity, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated using Fisher exact tests, risk ratios (RRs), Kaplan–Meier and Cox models, and robust modified Poisson regression. Exact one-sided 95% upper confidence bounds were calculated for zero HBVr events.

Results

Fifty patients comprised the HBVr-risk cohort, including 47 with resolved and 3 with chronic HBV infection. Anti-HBs positivity was more frequent in the Resolved than No group (89.4% vs 69.8%; P=0.040), as was pre-CAR-T antiviral prophylaxis (59.6% vs 34.9%; P=0.033).

No documented HBVr occurred during a median post-infusion follow-up of 153.5 days, including 0 of 47 patients with resolved HBV infection, 0 of 3 patients with chronic HBV infection receiving antiviral prophylaxis, and 0 of 19 patients with resolved infection who did not receive pre-CAR-T prophylaxis. In the overall 50-patient HBVr-risk cohort, the exact one-sided 95% upper confidence bound was 5.8%.

Resolved HBV infection was not associated with increased major toxicity. Any-grade cytokine release syndrome occurred in 80.9% of Resolved and 79.1% of No patients (RR, 1.02; 95% CI, 0.83-1.26; P=1.000), and grade 3-4 cytokine release syndrome occurred in 6.4% and 9.3%, respectively (RR, 0.69; 95% CI, 0.16-2.89; P=0.705). Immune effector cell-associated neurotoxicity syndrome occurred in 6.4% versus 4.7% (RR, 1.37; 95% CI, 0.24-7.82; P=1.000). Infection rates were 42.6% versus 37.2%; resolved HBV was not associated with infection after adjustment for age, prior hematopoietic stem cell transplantation, and CAR T-cell product origin (adjusted RR, 1.16; 95% CI, 0.69-1.93; P=0.579). Documented hepatitis occurred in 19.1% versus 18.6% and remained similar after adjustment for age and baseline alanine aminotransferase level (adjusted RR, 1.16; 95% CI, 0.50-2.68; P=0.725).

Among response-evaluable patients, ORR was 86.0% in the Resolved group and 82.9% in the No group (RR, 1.04; 95% CI, 0.86-1.25; P=0.768). Results were unchanged when unevaluable patients were classified as nonresponders. Resolved HBV infection was not independently associated with OS (adjusted hazard ratio, 1.12; 95% CI, 0.58-2.16; P=0.737) or PFS (adjusted hazard ratio, 0.86; 95% CI, 0.48-1.53; P=0.606).

Conclusions In this multicenter CD7 CAR T-cell cohort, no documented HBVr occurred among 50 patients with chronic or resolved HBV infection, while resolved HBV infection was not associated with excess toxicity, impaired response, or inferior survival. These findings provide clinically relevant reassurance that resolved HBV infection need not represent an absolute barrier to CD7 CAR T-cell therapy. The low observed HBVr burden also supports prospective investigation of whether preservation or reconstitution of CD7-negative T-cell and natural killer-cell compartments contributes to antiviral immune surveillance after CD7 CAR T-cell therapy.
Ruoxuan Zhang Jr: No relevant conflicts of interest to declare.